Nebula Research & Development LLC Takes Position in Castle Biosciences, Inc. (NASDAQ:CSTL)

Nebula Research & Development LLC bought a new stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 26,674 shares of the company's stock, valued at approximately $711,000. Nebula Research & Development LLC owned about 0.10% of Castle Biosciences as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD increased its position in shares of Castle Biosciences by 8.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 22,697 shares of the company's stock valued at $605,000 after purchasing an additional 1,837 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Castle Biosciences by 201.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 11,265 shares of the company's stock valued at $300,000 after acquiring an additional 7,524 shares during the last quarter. MetLife Investment Management LLC grew its position in Castle Biosciences by 11.4% during the fourth quarter. MetLife Investment Management LLC now owns 16,017 shares of the company's stock valued at $427,000 after acquiring an additional 1,645 shares during the last quarter. Natixis purchased a new position in shares of Castle Biosciences during the fourth quarter worth approximately $522,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Castle Biosciences by 15.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 999,466 shares of the company's stock worth $26,636,000 after acquiring an additional 134,645 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.

Castle Biosciences Trading Up 0.2 %

Shares of NASDAQ:CSTL traded up $0.04 during midday trading on Friday, hitting $19.35. 1,248,970 shares of the stock traded hands, compared to its average volume of 393,795. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $558.15 million, a PE ratio of 96.75 and a beta of 1.19. Castle Biosciences, Inc. has a one year low of $16.97 and a one year high of $35.84. The business's 50 day moving average is $20.43 and its two-hundred day moving average is $26.09.

Insider Buying and Selling at Castle Biosciences

In other news, insider Derek J. Maetzold sold 1,236 shares of Castle Biosciences stock in a transaction dated Monday, April 21st. The shares were sold at an average price of $21.52, for a total transaction of $26,598.72. Following the sale, the insider now owns 74,627 shares of the company's stock, valued at approximately $1,605,973.04. The trade was a 1.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Daniel Bradbury sold 7,867 shares of the business's stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total transaction of $221,613.39. The disclosure for this sale can be found here. Insiders sold 35,321 shares of company stock valued at $774,644 in the last 90 days. Insiders own 7.20% of the company's stock.

Analyst Upgrades and Downgrades

CSTL has been the topic of several recent research reports. Robert W. Baird increased their target price on shares of Castle Biosciences from $36.00 to $37.00 and gave the company an "outperform" rating in a report on Friday, February 28th. Guggenheim set a $30.00 price objective on Castle Biosciences and gave the company a "buy" rating in a research note on Friday, March 28th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $38.75.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.